



## Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference

May 7, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--May 7, 2020-- Intersect ENT, Inc. (Nasdaq: [XENT](#)), today announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference. The fireside chat will take place on Thursday, May 14, 2020 at 2:20 p.m. EDT.

To access the webcast, go to the "Investor Relations" page of the Company's website at [www.intersectENT.com](http://www.intersectENT.com). The webcast replay will be archived for approximately one month.

### **About Intersect ENT®**

Intersect ENT is a company transforming care for patients with ear, nose and throat conditions. The Company's steroid-releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

For additional information on the Company or the products including risks and benefits please visit [www.IntersectENT.com](http://www.IntersectENT.com). For more information about PROPEL® (mometasone furoate) sinus implants and SINUVA® (mometasone furoate) sinus implant, please visit [www.PROPELOPENS.com](http://www.PROPELOPENS.com) and [www.SINUVA.com](http://www.SINUVA.com).

Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc.

XENT-F

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200507005906/en/): <https://www.businesswire.com/news/home/20200507005906/en/>

Inquiries:

Intersect ENT, Inc.

Richard Meier

650.641.2105

[ir@intersectENT.com](mailto:ir@intersectENT.com)

Source: Intersect ENT, Inc.